Intelligence / Healthtech / PMA Approvals / Diasorin, INC.
Diasorin, INC.
27 Aug 2026: Device change approved (PMA) · LIAISON QuantiFERON-TB Gold Plus; LIAISON XL Control QuantiFERON-TB Gold Plus; LIAISON QuantiFERON-TB Gold Plus II; LIAI. Recorded in the openFDA device PMA data.
- Decided
- 27 Aug 2026
- Device
- LIAISON QuantiFERON-TB Gold Plus; LIAISON XL Control QuantiFERON-TB Gold Plus; LIAISON QuantiFERON-TB Gold Plus II; LIAI
- Specialty
- Microbiology
- Type
- Supplement (Normal 180 Day Track)
- Reason
- Labeling Change - Indications/instructions/shelf life/tradename
- Reference
- P180047 S043
- Location
- Stillwater, MN
A PMA approval is a high-risk device launch: reimbursement, distribution, clinical training and sales hires follow.
- Cardiovascular leads with 53 of 120, then Pathology (15).
- 35 added in the 30 days to 18 Nov 2026.
Find the decision makers at Diasorin, INC.
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.
Across AOS Research
Other records for Diasorin, INC. in our registers.
Source: openFDA device PMA data, data to 18 Nov 2026. Class III devices approved by FDA: original approvals and supplements that change the device (180-day, panel-track and special tracks). 30-day manufacturing notices are left out. AOS shows what the public record says; it does not verify or endorse the company.